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Autosomal dominant cerebellar ataxia-deafness and narcolepsy (ADCA-DN) and
Hereditary sensory neuropathy with dementia and hearing loss (HSN1E) are two rare,
overlapping neurodegenerative syndromes that have been recently linked to allelic
dominant pathogenic mutations in the DNMT1 gene, coding for DNA (cytosine-5)-
methyltransferase 1 (DNMT1). DNMT1 is the enzyme responsible for maintaining the
nuclear genome methylation patterns during the DNA replication and repair, thus
regulating gene expression. The mutations responsible for ADCA-DN and HSN1E affect
the replication foci targeting sequence domain, which regulates DNMT1 binding to
chromatin. DNMT1 dysfunction is anticipated to lead to a global alteration of the DNA
methylation pattern with predictable downstream consequences on gene expression.
Interestingly, ADCA-DN and HSN1E phenotypes share some clinical features typical of
mitochondrial diseases, such as optic atrophy, peripheral neuropathy, and deafness,
and some biochemical evidence of mitochondrial dysfunction. The recent discovery of a
mitochondrial isoform of DNMT1 and its proposed role in methylating mitochondrial DNA
(mtDNA) suggests that DNMT1 mutations may directly affect mtDNA and mitochondrial
physiology. On the basis of this latter finding the link between DNMT1 abnormal
activity and mitochondrial dysfunction in ADCA-DN and HSN1E appears intuitive,
however, mtDNA methylation remains highly debated. In the last years several groups
demonstrated the presence of 5-methylcytosine in mtDNA by different approaches,
but, on the other end, the opposite evidence that mtDNA is not methylated has also
been published. Since over 1500 mitochondrial proteins are encoded by the nuclear
genome, the altered methylation of these genes may well have a critical role in leading
to the mitochondrial impairment observed in ADCA-DN and HSN1E. Thus, many open
questions still remain unanswered, such as why mtDNA should be methylated, and how
this process is regulated and executed?
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DNA Methylation
Several epigenetic signals participate in cell speciﬁc gene expres-
sion, including DNA methylation and demethylation, post-
translational modiﬁcations of histone proteins (i.e., acetylation,
methylation, phosphorylation, and ubiquitination), incorpora-
tion of histone variants and gene regulation by non-coding RNAs
(Rivera and Ren, 2013; Kanherkar et al., 2014a). DNA methyla-
tion, which occurs in all prokaryotic and eukaryotic organisms,
with rare exception for yeast, roundworm, and fruit ﬂy, is a key
epigenetic process involved in the regulation of gene expres-
sion (Lande-Diner et al., 2007; Lee et al., 2010) and parental
imprinting (Sha, 2008; Ishida and Moore, 2013), in chromo-
some X inactivation (Straub and Becker, 2007) as well as in the
development of the immune system (Cedar and Bergman, 2011;
Kondilis-Mangum and Wade, 2013; Li et al., 2013) and in cellular
reprogramming (Reik, 2007; Krishnakumar and Blelloch, 2013;
Papp and Plath, 2013; Kanherkar et al., 2014b). Furthermore,
it is engaged in the maintenance of the genome integrity
through protection against endogenous retroviruses and trans-
posons (Howard et al., 2008). In humans aberrant DNA methy-
lation patterns are associated with several diseases, includ-
ing various cancers (Jones and Baylin, 2007; Esteller, 2008;
Iacobuzio-Donahue, 2009), immune system disorders (Feinberg,
2007) and neurodegeneration (Jakovcevski and Akbarian, 2012;
Qureshi and Mehler, 2013).
Classical Model of DNA Methylation
In prokaryotes, DNA methylation occurs on both cytosine and
adenine bases and is one of the host restriction systems to
distinguish self and non-self DNA (Jeltsch, 2006). In mam-
mals, following the classical model of DNA methylation, it
takes place in the cytosine residues at their C5 positions, pri-
marily in the CG dinucleotides (CpG), acting mainly as a
repressive tag to silence chromatin and inhibit transcription.
In the human genome there are 56 million CG sites, about
60–80% of which are methylated, corresponding to 4–6% of
all cytosines (Laurent et al., 2010). Methylation levels and pat-
terns are cell and tissue speciﬁc. In mammalian genomes, the
CpG are poorly represented compared to other dinucleotides,
because of the higher mutagenic property of the 5-methyl-
cytosine base compared to the unmethylated one (Pfeifer et al.,
2000). The irregular CpG distribution is reﬂected by their
depletion in intergenic and intragenic sequences, whereas their
presence is less suppressed in repetitive DNA (such as trans-
posons and retroviruses) and CpG islands, regions of at least
550 bp, with a ratio of observed CpG/expected CpG higher
than 0.65 (Takai and Jones, 2004). Around 70% of human genes
promoter regions present the CpG islands and an inverse
correlation between CpG islands density and the promoter
methylation status exists. Moreover, active genes usually show
hypomethylation at the transcriptional start site (TSS) and
high levels of methylation in the gene body, which is sup-
posed to block aberrant transcription initiation inside the gene,
avoiding the production of truncated mRNAs and proteins.
The splicing sites are regions characterized by a change in
DNA methylation, since exons have higher methylation than
introns, suggesting a strong implication of DNA methylation in
the splicing process (Laurent et al., 2010; Chatterjee and Vinson,
2012).
DNA Methyltransferase Enzymes
DNA methylation is catalyzed by a group of enzymes called
DNA (cytosine-5)-methyltransferases (DNMTs) that transfer
a methyl group from a cofactor molecule S-adenosyl-L-
methionine (AdoMet or SAM) to the C5 position of the
cytosine residues to generate 5-methylcytosine (5 mC) and
S-adenosyl-L-homocysteine (AdoHcy, SAH; Figure 1A).
The mammalian DNMT family includes four members:
DNMT1, DNMT3A, DNMT3B, and DNMT3L. These enzymes
FIGURE 1 | Schematic representation of DNA methylation. (A) DNA
(cytosine-5)-methyltransferases (DNMTs) transfer the methyl group at the DNA
cytosine ring carbon C5 by using S-adenosyl methionine (SAM) as methyl
donor. S-adenosyl homocysteine (SAH) is the cofactor product. (B) DNA
methylation: classical model. Maintenance versus de novo methylation. Figure
modified by Cheng and Blumenthal (2008).
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comprise two parts: a C-terminal catalytic portion and a
large N-terminal region of variable size containing reg-
ulatory domains involved in the interaction with DNA,
chromatin, and other proteins (Figure 2). Furthermore, the
N-terminal region contains 621 amino acids required for
discriminating between hemi-methylated and unmethy-
lated DNA. The C-terminal catalytic domain, being highly
conserved between eukaryotes and prokaryotes, is com-
posed by 500 amino acids and harbors the active center
of the enzyme, which contains amino acids motifs char-
acteristic of the cytosine-C5 methyltransferases, called the
“AdoMet-dependent MTase fold” (Jurkowska et al., 2011a).
Motifs I and X of this domain are involved in cofactor
binding whereas motifs IV, VI, and VIII have a catalytic
function. The non-conserved region between motifs VIII
and IX is the target recognition domain (TRD), crucial for
DNA recognition and speciﬁcity (Cheng, 1995; Jeltsch, 2002;
Cheng and Blumenthal, 2008). Considering the high variability
of the N-terminus of DNTMs, a detailed description of this
region for each DNMT isoforms will be provided in the following
paragraphs.
The initial methylation pattern is established by de novo
DNMTs (DNMT3 family in mammals). This pattern is perpet-
uated for the rest of the life (with small tissue-speciﬁc changes)
by a mechanism ﬁrst proposed by Holliday and Pugh (1975) and
Riggs (1975).
Each round of DNA replication produces hemimethylated
DNA with the methylation marks in the parental stand and
the new synthesized daughter unmethylated strand (Figure 1B).
The maintenance DNA methyltransferase (DNMT1 in mam-
mals), showing a preference for hemimethylated sites, copies the
existing methylation pattern (Jones and Liang, 2009; Denis et al.,
2011).
DNMT3 Family
During the embryogenesis the DNMT3 family establishes
the initial CpG methylation pattern (Chen and Li, 2006;
Jurkowska et al., 2011a). The DNMT3 family includes two active
FIGURE 2 | A schematic representation of the domain structure of
human DNMT isoforms. For human DNMT1, DNA methyltransferase
associated protein (DMAP), replication foci targeting sequence (RFTS), CXXC,
bromo-adjacent homology (nBAH/cBAH), and catalytic domains are
represented by cyan, blue, orange, violet, and yellow bars, respectively. For
human DNMT2, catalytic domain is represented by yellow bar. For human
DNMT3A, DNMT3B, and DNMT3L, PWWP, ADD, and catalytic domains are
represented by green, red, and yellow bars, respectively. In the catalytic domain
(yellow bar), the conserved C5 DNA MTase motifs in the C-terminal part of each
DNMT isoforms are labeled. The interdomain linker regions are shown as light
gray bars. Numbers in parentheses indicate the length of each protein. The
crystal structures of the human DNMT1 RFTS domain (residues 351–597, PDB
ID: 3EPZ; Syeda et al., 2011), human DNMT1 CXXC, nBAH/cBAH, and catalytic
domains bound to DNA-containing unmethylated CpG sites (residues
646–1600, PDB ID: 3PTA; Song et al., 2011), human DNMT2 catalytic domain
(residues 1–188 and 248–391, PDB ID: 1G55; Dong et al., 2001), human
DNMT3A PWWP (residues 275–427, PDB ID: 3LLR), and ADD domains
(residues 476–614, PDB ID: 3A1A; Otani et al., 2009; Wu et al., 2011,
respectively), human DNMT3B PWWP domain (residues 293–442; PDB ID:
3QKJ; Wu et al., 2011), human DNMT3L ADD domain (residues 34–277 and
279–380, PDB ID: 2PV0; Ooi et al., 2007), are shown. For further details see
“Text.”
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de novo DNMTs, DNMT3A, and DNMT3B, without signiﬁcant
preference between hemimethylated and unmethylated DNA,
and one catalytically inactive regulatory factor, the DNMT3-Like
protein (DNMT3L; Bestor, 2000; Jurkowska et al., 2011a).
Knockout of DNMT3A or DNMT3B is lethal, being both
essential for embryonic development in mice. Mouse DNMT3B
knockout embryos die in utero, whereas the DNMT3A knock-
out animals die shortly after birth (Okano et al., 1999). DNMT3L
knockout mice are viable, but male are sterile, failing to pro-
duce mature sperm (Hata et al., 2002). Mutations in the human
DNMT3B gene are associated with a rare autosomal disease,
called ICF (Immunodeﬁciency, Centromere instability, Facial
abnormalities) syndrome, which is accompanied by hypomethy-
lation of classical satellites of the pericentromeric regions of
chromosomes 1, 9, and 16, probably due to reduction of enzyme
catalytic eﬃciency or alteration of its localization (Xu et al.,
1999; Weemaes et al., 2013). De novo mutations in DNMT3A
have also been identiﬁed in patients with overgrowth disorders
(Tatton-Brown et al., 2014). Despite high sequence homology
and similar biochemical properties, DNMT3A and 3B show par-
tially non-overlapping biological functions with DNMT3A being
involved in the setting of parental imprints and DNMT3B in
the methylation of pericentromeric repeats (Okano et al., 1999;
Kaneda et al., 2004).
From the structural point of view, the DNMT3 enzymes con-
tain a N-terminal variable portion (around 280 and 220 amino
acids for DNMT3A and DNMT3B, respectively), followed by two
conserved regions: the regulatory PWWP and ADD domains and
C-terminal catalytic portion. DNMT3L lacks the PWWP domain
as well as the DNMTs motifs IX and X and all the important cat-
alytic residues in its C-terminal portion (Figure 2). The PWWP
is a variable module of 100–150 amino acids characterized by the
presence of a strictly conserved proline-tryptophan-tryptophan-
proline motif, also found in chromatin associated eukaryotic pro-
tein from yeast to mammals. It comprises a globular domain with
a ﬁve-stranded β-barrel followed by a ﬁve-helix bundle (Figure 2;
Qiu et al., 2002; Chen et al., 2004). In vitro experiments showed
that the PWWP domain of DNMT3B mediate DNA binding,
but it is not required for CpG methylating activity (Qiu et al.,
2002). Subsequently, it has been demonstrated that it exhibits
a dual function: binding to both DNA and methylated lysine
on histone proteins (Chen et al., 2004; Dhayalan et al., 2010;
Wu et al., 2011). The ADD domain (ATRX-DNMT3-DNMT3L),
also known as PHD domain (plant homodomain), is present in
all the proteins belonging to DNMT3 family and in the ATRX
(alpha thalassemia/mental retardation syndrome X-linked) pro-
tein. This domain is a cysteine-rich module that binds zinc
ions (comprising six CXXC motifs; Figure 2) and constitutes a
platform for various protein–protein interactions. It has been
reported that DNMT3L, which only owns this characteristic
motif, recognizes speciﬁcally the unmethylated lysine 4 of his-
tone H3 through its ADD domain and induces de novo DNA
methylation by recruitment or activation of DNMT3A, thanks to
an interaction between its C-terminal domain and the catalytic
portion of DNMT3A. These data support the idea that DNMT3L
has the dual function of binding the unmethylated histone tail
and activating DNA methyltransferase (Jia et al., 2007; Ooi et al.,
2007). Nevertheless, the ADD domains of DNMT3A and 3B
share considerable homology with DNMT3L and it has been
reported a direct binding of the DNMT3A and DNMT3B ADD
domains to H3 tails unmodiﬁed at lysine 4 (Otani et al., 2009;
Zhang et al., 2010). Since the ADD domains of DNMT3A/B and
DNMT3L clearly show the same binding speciﬁcity, the recruit-
ment of DNMT3A to chromatin with unmethylated H3 tail is
probably not the primary function of DNMT3L (Zhang et al.,
2010).
Jurkowska et al. (2011b) reported that DNMT3A forms
oligomers predicted to bind several DNA molecules oriented in
parallel and required to tightly tie to heterochromatin by the
ADD and PWWP domains, which recognize H3 tails unmodi-
ﬁed at lysine 4 and H3 trimethylated at lysine 36, respectively
(Dhayalan et al., 2010; Zhang et al., 2010). In addition, the associ-
ation of the DNMT3A oligomers to DNMT3L changes its subnu-
clear localization, from heterochromatin to euchromatin, thereby
increasing its availability and DNA methylation activity for
the generation of DNA methylation imprints (Jurkowska et al.,
2011b).
DNMT1
Whereas DNMT3 family works as de novo methylases, DNMT1
maintains the existing pattern of methylation during chromo-
somes replication (Chen and Li, 2006; Jurkowska et al., 2011a)
and repair (Mortusewicz et al., 2005; Loughery et al., 2011).
Human DNMT1, a large enzyme of 1616 amino acids, is
the most abundant DNMT involved in preserving and prop-
agating the existing methylation patterns during cell division
(Jurkowska et al., 2011a; Kar et al., 2012). It shows a preference
for hemimethylated DNA (Goyal et al., 2006) and it is localized
at the DNA replication foci during the S-phase of cell cycle
(Leonhardt et al., 1992). In addition, DNMT1, being a highly
processive enzyme, is able to methylate long stretches of DNA
without dissociation (Hermann et al., 2004; Vilkaitis et al., 2005).
These two features make it suitable for its role in the maintenance
of methylation patterns. The expression of DNMT1 is ubiquitous
and high in proliferating cells and varies in a cell-cycle-dependent
manner, being maximal during the S-phase and extremely low
in non-dividing cells (Robertson et al., 1999; Kimura et al., 2003).
Concerning the subcellular localization of DNMT1, it is diﬀusely
distributed in the nucleus during the interphase and moves to
the replication foci for early and mid S-phase creating a char-
acteristic punctuate pattern (O’Keefe et al., 1992; Easwaran et al.,
2008). DNMT1 mouse knockout shows extensive demethylation
of the genome and embryonic lethality shortly after gastrula-
tion, underlying the crucial role of DNMT1 in early development.
Embryonic stem cells lacking DNMT1 are viable, despite the low
level of DNA methylation, but die after diﬀerentiation induc-
tion (Li et al., 1992; Chen et al., 1998). Complete inactivation of
DNMT1 in human colorectal carcinoma cells leads to severe
mitotic defects and progressive cell death (Chen et al., 2007).
Mutations aﬀecting the DNMT1 gene have been associ-
ated with two distinct autosomal dominant neurodegenerative
diseases: hereditary sensory and autonomic neuropathy with
dementia and hearing loss type 1E (HSN1E) and autosomal
dominant cerebellar ataxia-deafness and narcolepsy (ADCA-DN;
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Klein et al., 2011; Winkelmann et al., 2012). All these mutations
are localized in the DNA replication foci targeting sequence
(RFTS) domain, essential inmediating the association of DNMT1
to heterochromatin. Mutations in exon 20 of DNMT1 have been
associated with HSN1E, whereas mutations in exon 21 have been
found in ADCA-DN (Klein et al., 2013).
From the structural point of view, DNMT1 is a multi-
domain enzyme composed by a N-terminal regulatory region
and a C-terminal catalytic domain joined by a series of
KG (lysine-glycine) repeats (Figure 2; Dhe-Paganon et al., 2011;
Jurkowska et al., 2011a; Kar et al., 2012). The N-terminal portion
contains several motifs:
• DMAP1 (DNA methyltransferase associated protein 1)
charged rich domain is involved in the interaction of DNMT1
with the transcriptional repressor DMAP1 as well as in the
stability of the enzyme and in its binding to DNA CpG sites
(Rountree et al., 2000; Ding and Chaillet, 2002).
• PBD (PCNA-proliferating cell nuclear antigen-binding)
domain address DNMT1 to the replication foci through the
interaction between DNMT1 and PCNA.
• NLS (nuclear localization sequence) are at least three.
• RFTS (replication foci targeting sequence) is crucial for the
localization of DNMT1 at the centromeric chromatin and
replication foci as well as for its dimerization (Easwaran et al.,
2008; Fellinger et al., 2009).
• CXXC zinc domain, similar to the cysteine-rich motif present
in other chromatin associated proteins. It contains eight con-
served cysteine residues clustered in two CXXCXXC repeats
that bind to two zinc ions and is necessary for the recognition
of unmethylated CpG, thus inﬂuencing the catalytic activity of
the enzyme (Pradhan et al., 2008).
• PBHD (polybromo homology domain) domain is composed
by the BAH1 and BAH2 (Bromo-adjacent homology 1 and
2) motifs, typical of proteins involved in transcriptional reg-
ulation. It has been proposed to act as a protein–protein
interaction module specialized in gene silencing even if its
functional role in DNMT1 remain unknown.
Thus, the N-terminal regulatory region is designed to rec-
ognize the methylation target site (DMAP1, PBD, and RFTS
domains), to bind nucleic acids trough an allosteric site (CXXC
domain) and to allow interaction with other proteins (PBHD
domains), making DNMT1 ideally suited for its role as the
maintenance methyltransferase.
The KG linker between the N- and C-terminal regions of the
enzyme is composed by a series of lysine and glycine residues,
which might contribute to address DNMT1 to the region next to
the replication fork.
Finally, the C-terminal region encloses the catalytic center
of the enzyme bearing the conserved motifs I–X, and is folded
in large and small domains, separated by a huge cleft. The
large domain (motifs I-VIII and part of motif X) participates in
SAM cofactor binding substrate (cytosine) targeting and other
essential catalytic events. The small domain includes a variable
region between motif VIII and IX, named TRD (target recog-
nition domain), the conserved motif IX and part of motif X.
The catalytic domain allows the binding of the target DNA in
the active site and various other regulatory molecules in the
allosteric sites, which support a multiple levels of enzyme regula-
tion (Dhe-Paganon et al., 2011; Jurkowska et al., 2011a; Kar et al.,
2012).
In order to avoid runaway methylation, DNMT1 undergoes
to several auto-inhibitory mechanisms. In particular, to keep
DNMT1 inactive the RFTS domain is positioned and stabilized
deep inside the catalytic domain in a task where the hemimethy-
lated DNA is expected to ﬁt, thus, masking the catalytic core of
the enzyme (Qin et al., 2011; Syeda et al., 2011; Bashtrykov et al.,
2014). The auto-inhibitory function of the CXXCdomain is more
controversial. Song et al. (2011). reported that CXXC speciﬁcally
binds to unmethylated CpG, activating the CXXC-BH21 linker,
which then occupies the catalytic pocket and interferes with its
function. By contrast, Bashtrykov et al. (2012) refused this auto-
inhibitory mechanism, proposing instead that the recognition of
the hemimethylated state of target sites resides within the cat-
alytic domain. While the unmethylated DNA emerges from the
replication fork, DNMT1 is tethered and kept auto-inhibited to
avoid unauthorized de novo methylation of the DNA. As soon as
the hemimethylated sites are released from the replication com-
plex, the TRD region of DNMT1 in combination with UHRF1
(ubiquitin-like with PHD and ring ﬁnger domains 1) recognizes
and marks them as prime targets for methylation to guarantee
the correct methylation patterns across successive generations
(Kar et al., 2012).
DNMT2
DNA (cytosine-5)-methyltransferases 2 is the smallest mam-
malian DNMT, now named TRDMT1, which has the poten-
tial to methylate RNA instead of DNA (Goll et al., 2006;
Schaefer and Lyko, 2010). It completely lacks the regulatory N-
terminal region and the C-terminal domain contains all 10
sequence motifs that are conserved among DNMTs, includ-
ing the consensus S-adenosyl-L-methionine-binding motifs
(Okano et al., 1998; Dong et al., 2001; Figure 2). Despite the high
sequence and structural similarity with other DNMTs and its
capability to bind the DNA, DNMT2 has failed to show a signiﬁ-
cant transmethylase activity (Hermann et al., 2003). Nonetheless,
it methylates cytosine 38 in the anticodon loop of tRNAAsp
(Goll et al., 2006), by using a DNA methyl transferase-like cat-
alytic mechanism (Jurkowski et al., 2008). Thus, DNMT2 seems
to have intermediate properties between a DNA methyl trans-
ferase and a RNA methyl transferase, with which it shares the
structural/catalytic features and the nuclear-cytoplasmic localiza-
tion, respectively (Schaefer et al., 2008).
Stochastic Model of DNA Methylation
For long time the classical model of DNA methylation at
CpG sites in mammals, with the involvement of both DNMT3
and DNMT1 (i.e., de novo and maintenance DNA methyl-
transferases, respectively), has been considered a paradigm
for epigenetic information transfer (Holliday and Pugh, 1975;
Riggs, 1975). Over the years, several experimental observa-
tions highlighted that the site-speciﬁc maintenance methyla-
tion model had to be revised. Thus, Jeltsch and Jurkowska
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(2014) proposed a modiﬁed stochastic DNA methylation
model which includes a new description of both de novo
and maintenance methylation process at CpG and non-CpG
sites.
An eﬃcient methylation of both DNA strands, starting from
unmethylated DNA, can be achieved by the tight cooperation
of DNMT3 enzymes with DNMT1. Thus, de novo and mainte-
nance methylation could not be regarded as two distinct events.
DNMT3 enzymes, and in particular DNMT3A, can bind adjacent
DNA molecules, but only one of the two strands is preferentially
methylated. By contrast, the hemi-methylated DNA is the favorite
substrate for DNMT1, which copies the methylation on the sec-
ond strand (Fatemi et al., 2002). In addition, DNMT1 shows
considerable de novomethylation activity on unmethylated DNA
both in vitro (Goyal et al., 2006) and in vivo, as observed in
DNMT3A/3B double knockout embryos (Okano et al., 1999).
Arand et al. (2012). have conﬁrmed these results by reporting
DNMT1-dependent de novo methylation in cells with single
or combined DNMTs knockout. On the other side, deletion of
DNMT3A/3B or DNMT3B alone led to a reduction of main-
tenance DNA methylation at repetitive elements, despite the
presence of functional DNMT1 (Chen et al., 2003; Dodge et al.,
2005; Arand et al., 2012).
Thus, neither de novo methylation nor maintenance methy-
lation can be exclusively assigned to DNMT3A/3B or DNMT1,
respectively, but a synchronized cooperation of all the DNMTs
seems crucial.
The classical model of maintenance methylation assumes that
the methylation patterns of single CpG sites are stably inherited
and that exists for this purpose a perfect enzyme, characterized by
a working eﬃciency of 100%.
In reality, average methylation densities of DNA regions
are maintained, instead of exact CpG site-speciﬁc methylation
patterns (Zhang et al., 2010), and changes in methylation lev-
els occur through stochastic processes (Landan et al., 2012). In
fact, despite the 10–40-fold preference of DNMT1 for hemi-
methylated DNA, this feature is not enough to copy accurately
the site-speciﬁc methylation status of around 56million CpG sites
in the human genome over several rounds of DNA replication
(Jeltsch and Jurkowska, 2014).
In addition, patterns of non-CpG DNA methylation, typical
of plants, have been reported also in the human genome, taking
place in CpA sites, and speciﬁcally introduced by DNMT3A. This
clearly indicates a permanent de novomethylation activity of this
enzyme, which is not in agreement with the classical methylation
model (Arand et al., 2012; Guo et al., 2014).
Finally, also the DNA demethylation has to be considered in
the establishment and maintenance of DNAmethylation pattern.
This process could be passive, during the replication, or active,
performed by the family of ten eleven translocation (TET) dioxy-
genases. These enzymes oxidize the methyl groups of methyl-
cytosine and are expressed both during early development and
also in later stages, suggesting a permanent DNA demethyla-
tion. Hydroxymethylation of DNA by TET enzymes has been
proposed to keep CpG islands in unmethylated state by coun-
teracting stochastic DNA methylation (Kohli and Zhang, 2013;
Wu and Zhang, 2014).
In conclusion, the DNA methylation is inﬂuenced by all the
events above described, that are combined in the stochastic model
of Jeltsch and Jurkowska (2014):
• DNA methylation at each site is determined by the local rates
of methylation and demethylation
• The local rates of methylation depend on targeting/regulation
of DNMTs/demethylases and on chromatine remodel-
ing/DNA accessibility
• DNA methylation occurs on both CpG and non-CpG sites de
novo and maintenance methylation are combined in a uniﬁed
mechanism
• The average DNA methylation level of DNA regions is inher-
ited rather than the methylation state of individual CpG
sites.
Mitochondrial DNA Methylation
Unlike nuclear DNA, the methylation of mtDNA is a highly
controversial topic that after 40 years is still matter of debate
among researchers. In fact, although recent studies have demon-
strated the presence of 5 mC in mtDNA, skepticism regarding
the sensitivity and reproducibility of the methods used and the
putative biological function of methylation in mitochondria still
remains. Indeed, the observed methylation levels are very low
(1–5%) and, furthermore, mtDNA has a diﬀerent organization
compared to nuclear DNA (i.e., no histones, lack of introns,
multicopy genomes), which should imply a diﬀerent regula-
tory mechanism of gene expression through DNA methylation.
In fact, mammalian cells typically contain 1,000–10,000 copies
of mtDNA, which are organized into nucleoprotein complexes
termed nucleoids, being TFAM (mitochondrial transcriptor fac-
tor A) the main protein component. The TFAM/mtDNA ratio
ﬁnely regulates the fraction of active mtDNA molecules available
for mitochondrial replication/transcription (Bogenhagen, 2012;
Campbell et al., 2012; Farge et al., 2014).
The ﬁrst approaches to investigate mtDNA methylation date
back to 1970s, when Vanyushin et al. (1971) found a DNMT
activity in mitochondria isolated from loach embryos, demon-
strated the presence of 5 mC in mtDNA extracted from beef heart
(Vanyushin and Kirnos, 1974) and evidenced a diﬀerent speci-
ﬁcity for DNA methylases isolated from nucleus and mitochon-
dria, being the mitochondrial speciﬁc for mono-pyrimidines and
the nuclear for di- and tri-pyrimidines (Vanyushin and Kirnos,
1977). However, in the same years the absence of 5 mC in
mtDNA from mouse, hamster, frog, and HeLa cells was also
reported (Nass, 1973; Dawid, 1974). Shmookler and Goldstein
(1983) and Pollack et al. (1984), studying both human ﬁbroblasts
and mouse ﬁbroblastoid cells, clariﬁed that methylation occurred
in mtDNA with a frequency of 1.5–5% and only in CpG di-
nucleotides, which, however, are underrepresented in mtDNA
(Pollack et al., 1984; Cardon et al., 1994). After many years, in
2004, the presence of methylated cytosines in mtDNA, from gas-
tric and colorectal cancers, was once again denied using bisulﬁte-
PCR-single-stranded DNA conformation polymorphism on
three selected regions of mtDNA containing 37 CpG sites
(Maekawa et al., 2004).
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Rebelo et al. (2009) failed to observe mtDNA methylation in
human osteosarcoma 143B, HEK293, and HeLa cells, under stan-
dard culture conditions, but the same authors also reasoned
that percentages of methylation <5% have not been detected
by the approach employed (site-speciﬁc methylation restric-
tion enzymes). However, in this study, some methylation of
mtDNA was observed after the induced-expression of two dif-
ferent mitochondria-targeted bacterial methyltransferases and,
additionally, the levels of this methylation increased during
mtDNA replication, when it is assumed that nucleoids are remod-
eled and mtDNA could be less protected by proteins (i.e., TFAM)
and more accessible to DNMTs (Rebelo et al., 2009).
The issue of mtDNA methylation came back again in
2011, when two diﬀerent groups demonstrated the presence
of 5 mC and DNMTs in mitochondria through novel and
more sensitive approaches (Chestnut et al., 2011; Shock et al.,
2011). Surprisingly, a mitochondria targeted DNMT1 isoform
(mtDNMT1), conserved in diﬀerent species, has been found
by Shock et al. (2011); the mtDNMT1 seems to be translated
from an unconventional ATG site, located immediately upstream
of the canonical one, and localized to mitochondria where it
bounds to mtDNA. Moreover, the mtDNMT1 gene expression
was induced by NRF1 and PGC1α, two master regulators of
mitochondrial biogenesis, in HCT116 cells (Shock et al., 2011).
Interestingly, gene expression of mtDNA-encoded genes was
altered after mtDNMT1 over-expression, with reduced levels of
MT-ND6 in the L-strand and increased levels of MT-ND1in the
H-strand, suggesting an opposite role for mtDNMT1, and cyto-
sine methylation in the two strands; however, the expression
levels of MT-CO1 and MT-ATP6, both in the H-strand, were
unaltered (Shock et al., 2011). The authors speculate that mtD-
NMT1 interferes with MTERF-dependent transcription termina-
tion, inducing an increased transcription of MT-ND1 through
the HSP1, with no eﬀects on the polycistronic mRNA produced
by HSP2. Lastly, in this study the presence of 5 mC in mtDNA
was demonstrated by a methylated DNA-immunoprecipitation
(MeDIP) approach, followed by real time-PCR (Shock et al.,
2011).
Concomitantly, Chestnut et al. (2011) demonstrated the pres-
ence of DNMT3A in mitochondria isolated from mouse brain
and from human motor cortex, whereas DNMT1 was faintly
detectable in mitochondria from these tissues. Furthermore,
co-localization of 5 mC and mitochondria was shown by
immunoﬂuorescence experiments using antibodies recognizing
5 mC and a speciﬁc mitochondrial marker (superoxide dismutase
isoform 2, SOD2; Chestnut et al., 2011).
The mtDNA methylation was also investigated by a liq-
uid chromatography-electrospray ionization tandem-mass spec-
trometry (LC-ESI-MS) method, proving the existence of 5 mC in
the mitochondrial genome (Infantino et al., 2011), and soon after
also 5 hmC have been identiﬁed inmtDNA by an ELISA approach
(Dzitoyeva et al., 2012).
In a study focused on the intragenic methylation of PolgA in
diﬀerent mouse cells/tissues as possibly correlated with PolgA
expression and mtDNA content regulation, the authors found
in the eluted fraction of MeDIP analysis some mtDNA encoded
genes (mt-cytb, mt-co1) and the D-loop region, indicating that
these genes have 5 mC and 5 hmC, although at very low levels
(Kelly et al., 2012).
Pirola et al. (2013) further evidence of methylated mtDNA has
been published. The methylation of MT-ND6, MT-CO1 and of
the D-loop of mtDNA was assessed by quantitative methylation
speciﬁc-PCR in the context of non-alcoholic fatty liver disease.
The authors found a signiﬁcant association between the condition
of non-alcoholic steatohepatitis (NASH) and the methylation of
MT-ND6 gene, which inversely correlates with MT-ND6 tran-
scription and protein expression in the liver of subject aﬀected
by NASH (Pirola et al., 2013).
The methylation of the D-loop region was also conﬁrmed
in mammals by bisulﬁte-sequencing (30 clones for each sam-
ple sequenced) and by MeDIP (Bellizzi et al., 2013). Methylation
was limited to the L-strand of the D-loop and the majority of
methylated cytosines were located outside the CpG nucleotides;
diﬀerent tissues were analyzed (blood cells, ﬁbroblasts, HeLa
cells) and tissue-speciﬁc patterns of methylation were identi-
ﬁed, HeLa cells showing the highest percentage of methylated
cytosines (Bellizzi et al., 2013). In the same study, DNMT1 and
DNMT3B expression in mitochondria from HeLa and mouse
3T3-L1 cells was evidenced (Bellizzi et al., 2013).
On the contrary, Wong et al. (2013) proved that in mouse
skeletal muscle DNMT1 was not present within the organelle,
but probably bound to the outer membrane (detectable in the
crude mitochondrial fraction), whereas DNMT3A was present in
the pure mitochondrial fraction isolated from both mouse skele-
tal muscle and spinal cord; DNMT3B was not detectable in any
of the mitochondrial preparations. DNMT3A was also present
in mitochondria from human cerebral cortex, but not in mito-
chondria from HEK293 cells, showing a preferential expression
in mitochondria from excitable tissues in humans and mouse
(Wong et al., 2013). In addition, methylated cytosines in the
mouse D-loop and mt-rnr2 (coding for 16S RNA) were iden-
tiﬁed by bisulﬁte treatment and pyrosequencing, and diﬀerent
levels of methylation in brain (highest percentage of 5 mC),
liver and testes were shown (Wong et al., 2013). Moreover, as
previously observed by Chestnut, the co-localization of 5 mC,
and mitochondria by immunoﬂuorescence was conﬁrmed and
interestingly, it was observed a co-localization of 5 mC with
autophagosome (LC3Apositive staining), indicating thatmtDNA
methylation may be involved in mitophagy (Wong et al., 2013).
Also Byun et al. (2013) carried out bisulﬁte-pyrosequencing to
investigate methylation of three mtDNA regions, MT-TF (tRNA
phenylalanine gene, two CpG sites), MT-RNR1 (12S RNA gene,
two CpG sites), and the D-loop (three CpG sites), in association
with eﬀect of airborne pollutants. The authors were able to detect
around 5–6% of 5 mC in the selected regions.
Hong et al. (2013) critically revised all methods employed
to quantify methylated mtDNA in the last years. Contextually,
these authors established the absence of CpG methylation in
human mtDNA performing bisulﬁte-sequencing and analyzing
data of bisulﬁte-next generation sequencing (NGS) previously
published by Akalin et al. (2012) andHong et al. (2013). Bisulﬁte-
sequencing failed to reveal 5 mC in four selected mtDNA regions
(MT-RNR1, MT-RNR2, MT-CO2, MT-ATP6) of HEK293 cells,
and identiﬁed very low frequencies of 5 mC in the same regions
Frontiers in Genetics | www.frontiersin.org 7 March 2015 | Volume 6 | Article 90
Maresca et al. DNMT1 and mtDNA methylation
of HCT116 and blood cells mtDNA (<0.5%), considered not
relevant because comparable to the non-convertion rate of bisul-
ﬁte; cross-contamination of nuclear DNA sequences of mito-
chondrial origins (NUMTs; Lascaro et al., 2008) has been also
excluded based on the speciﬁcity of the analyzed regions for
mtDNA sequence (Hong et al., 2013). Comparable levels of 5 mC
(<0.5%), both in CpG or not-CpG sites, came from the re-
analysis of bisulﬁte-NGS data on HCT116 cells previously pub-
lished (Akalin et al., 2012), but the mean coverage obtained of
94x may be not suﬃcient, considering that HCT116 cells have
a mtDNA content of about 4000 copies, as mentioned by the
authors (Hong et al., 2013).
Lastly, a comparative analysis of mitochondrial methylomes
in 39 diﬀerent cell lines was carried out extracting public
data from the NIH Roadmap Epigenomics project (Ghosh et al.,
2014). The re-analyzed data, deriving from MeDIP-sequencing
included human brain, breast, blood, penis, and two cell lines,
H1 and neurosphere cultured cells; moreover, some tissues
were analyzed at diﬀerent developmental time points. The
authors identiﬁed tissue- and development-speciﬁc pattern of
5 mC methylation in mtDNA, with MT-ND6 and MT-ATP6
showing progressive reduction in methylation correlated with
brain development. However, also in this case, methylated
cytosines resulted underrepresented (<0.5%) and an extremely
low minimum coverage of 5x was considered (Ghosh et al.,
2014).
In conclusion, since 2011 several studies claimed the occur-
rence of mtDNA methylation, but a few others also asserted
the absence of 5 mC in mtDNA (Figure 3). Many of the pub-
lished approaches had some limitations, such as the reproducibil-
ity of the methods based on the use of antibodies (ELISA,
MeDIP), or the enrichment by ampliﬁcation before sequenc-
ing that may create a bias, or the very low coverage con-
sidered for the analysis of NGS data that may inﬂuence the
quantiﬁcation of 5 mC referred to total mtDNA copies. In
fact, the analysis of mtDNA methylation should take into
account that the mitochondrial genome is multicopy, diﬀer-
ing for copy number depending on cell types and tissues
(Campbell et al., 2012). None of the sequencing studies cited
above have considered the percentage of methylated sites respect
to total mtDNA molecules present in the cells/tissues analyzed
(“methylation heteroplasmy”), but only the percentage of 5 mC
respect to total cytosines, as is usually done for the nuclear
genome.
The scenario becomes even blurrier when considering the
the controversial results on DNMTs localization (Tables 1 and 2),
since DNMT1 presence within mitochondria was demonstrated
(Shock et al., 2011; Bellizzi et al., 2013), and then denied by
FIGURE 3 | Chronological sequence of mtDNA methylation studies. Schematic representation of all the studies which support or denied the mtDNA
methylation.
Frontiers in Genetics | www.frontiersin.org 8 March 2015 | Volume 6 | Article 90
Maresca et al. DNMT1 and mtDNA methylation
TABLE 1 | Mitochondrial localization of DNA
(cytosine-5)-methyltransferases – DNMT1, DNMT3A, and DNMT3B, as
evaluated by Western blot, in different human cell types and tissues.
DNA methyl-
transferase
Mitochondrial
localization
Organism Cell
type/tissue
Reference
DNMT1 Yes Human HCT116 Shock et al.
(2011)
DNMT1 Yes Human HEK293 Chestnut et al.
(2011)
DNMT1 Yes Human HeLa Bellizzi et al.
(2013)
DNMT3A Yes Human HEK293 Chestnut et al.
(2011)
DNMT3A Yes Human Frontal
cortex
Wong et al.
(2013)
DNMT3A No Human HEK293 Wong et al.
(2013)
DNMT3B Yes Human HeLa Bellizzi et al.
(2013)
TABLE 2 | Mitochondrial localization of DNMT1, DNMT3A, and DNMT3B,
as evaluated by Western blot, in different mouse cell types and tissues.
DNA
methyl-
transferase
Mitochondrial
localiza-
tion
Organism Cell type/tissue Reference
DNMT1 Yes Mouse MEF Shock et al.
(2011)
DNMT1 Yes Mouse NSC34 Astrocyte
Microglia
Chestnut et al.
(2011)
DNMT1 Yes Mouse 3T3-L1 Bellizzi et al.
(2013)
DNMT1 No Mouse Adult skeletal
muscle
Wong et al.
(2013)
DNMT3A No Mouse MEF Shock et al.
(2011)
DNMT3A Yes Mouse NSC34 Astrocyte
Microglia
Chestnut et al.
(2011)
DNMT3A Yes Mouse Adult skeletal
muscle, brain,
spinal cord, heart,
testes, spleen
Wong et al.
(2013)
DNMT3B No Mouse MEF Shock et al.
(2011)
DNMT3B Yes Mouse 3T3-L1 Bellizzi et al.
(2013)
DNMT3B No Mouse Adult skeletal
muscle
Wong et al.
(2013)
Wong et al. (2013), who in addition observed DNMT3A within
mitochondria, but not DNMT3B, which, however, has been
detected in these organelles by others (Bellizzi et al., 2013).
Therefore, it remains truly unclear which DNMTs might be
implicated in mtDNAmethylation. Overall, further experiments,
focused on both global/site-speciﬁc methylation and the func-
tional eﬀects of this modiﬁcation are necessary to unequivo-
cally demonstrate methylation of the mitochondrial genome,
its biological function, and the possible links to pathological
conditions.
Defective DNA Methylation and
Neurological Diseases
Altered DNA methylation is a common hallmark of cancer, and
200, 590, and 320 somatic mutations in DNMT1, DNMT3A,
and DNMT3B, respectively, have been reported in the catalog
of somatic mutations in cancers (COSMIC). Up and down-
regulation of DNMTs has also been observed in diﬀerent types of
cancer (Forbes et al., 2008; Subramaniam et al., 2014; Wu et al.,
2014).
In addition to cancer, alterations of the DNA methylation
machinery also cause a few neurodegenerative and neurodevel-
opmental diseases, some of these recently described thanks to
whole-exome sequencing (Klein et al., 2011; Winkelmann et al.,
2012; Tatton-Brown et al., 2014). Genetic defects may produce
an epigenetic deregulation at diﬀerent levels, aﬀecting both
the enzymes responsible for de novo/maintenance methylation
(DNMT3/DNMT1), or proteins with a role in the recogni-
tion and binding of CpG methylated sites (MBDs, MeCP2;
Weissman et al., 2014). As mentioned previously, in Klein et al.
(2011) and Winkelmann et al. (2012), two independent exome-
sequencing studies revealed mutations in the RFTS domain of
DNMT1 gene causing two neurodegenerative disorders with
overlapping features: hereditary sensory HSN1E and ADCA-DN.
More recently, de novo mutations in DNMT3A gene aﬀecting
functional conserved domains of the protein, have been iden-
tiﬁed by exome-sequencing in patients with overgrowth dis-
orders (Tatton-Brown et al., 2014), resembling clinical features
of histone defects and imprinting disorders (Weissman et al.,
2014).
Besides primary epigenetic defects, deregulation of DNA
methylation may also inﬂuence the pathogenesis of other neu-
rodegenerative disorders, like amyotrophic lateral sclerosis (ALS)
or Alzheimer disease (AD), Parkinson disease (PD), or neurode-
velopmental diseases, such as Down syndrome (DS; Lu et al.,
2013). Global DNA hypomethylation in AD has been evi-
denced in a post-mortem study of monozygotic twins discordant
for AD (Mastroeni et al., 2009) and later conﬁrmed by others
(Sung et al., 2011; Chouliaras et al., 2013), whereas global hyper-
methylation has been described in other cases (Bakulski et al.,
2012; Rao et al., 2012; Coppieters et al., 2014). In contradic-
tion, Lashley et al. (2014) excluded alterations in global DNA
methylation and hydroxymethylation in AD. Hypomethylation
of speciﬁc genes related to AD (i.e., PSEN1, NEP, BIN1) have
also been observed (Lu et al., 2013; Yu et al., 2014). An addi-
tional link between DNA methylation and AD came from the
association of the chromosome location of DNMT1 (19p13.2)
with familial late-onset AD (FLOAD; Wijsman et al., 2004),
although sequencing of exon 20 and 21 of DNMT1 in 364
FLOAD cases failed to identify pathogenic mutations in these
regions, but only known polymorphisms with expected minor
allele frequencies based on European HapMap data (Klein et al.,
2013).
Hypomethylation of intron 1 of the α-synuclein (SNCA)
gene might be relevant for PD pathogenesis, inducing an
increased expression of α-synuclein in the substantia nigra
of PD patients and possibly contributing to the Lewy Body
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formation (Jowaed et al., 2010; Matsumoto et al., 2010; Lu et al.,
2013). Moreover, low levels of nuclear DNMT1 in post-mortem
brain of PD patients have been observed, indicating a pos-
sible link between SNCA hypomethylation and the methylase
(Desplats et al., 2011).
DNA methylation seems to have a role also in the pathogen-
esis of ALS, as proposed by Chestnut et al. (2011), by demon-
strating that the levels of DNMT3A, DNMT1, and 5 mC
are increased in motor neurons of ALS aﬀected patients.
Furthermore, abnormal mtDNA methylation has been found in
ALS (Wong et al., 2013) and also in patients aﬀected by Down’s
syndrome (Infantino et al., 2011), and for both diseases a mito-
chondrial dysfunction has been documented (Valenti et al., 2011;
Cozzolino et al., 2013).
Based on the mounting evidence of mitochondrial dysfunc-
tion in AD and PD, including organelle bioenergetics, dynamics,
and quality control (Schon and Przedborski, 2011; Burté et al.,
2015), DNAmethylation may inﬂuence the pathogenesis of these
neurodegenerative diseases, acting both on nuclear and mito-
chondrial DNAs. Moreover, mitochondria participate in the pro-
duction of the universal methyl donor SAM, through synthesis
of ATP and folate, whose deﬁciency, together with high levels
of homocysteine, have been associated with dementia, and neu-
rodegenerative diseases, including AD and PD (Iacobazzi et al.,
2013; Ansari et al., 2014). To the best of our knowledge, mtDNA
methylation has never been investigated in AD and PD, and nei-
ther methylation of nuclear genes encoding for mitochondrial
proteins.
ADCA-DN and HSN1E: Defective
Methylation Diseases with
Mitochondrial Involvement
Hereditary sensory neuropathy with dementia and hearing loss
(OMIM 614116), an adult-onset neurodegenerative disorder,
is the ﬁrst Mendelian inherited “methylopathy” identiﬁed due
to mutations in the DNMT1 gene aﬀecting the RFTS domain
(Klein et al., 2011). Shortly after, another adult-onset neurode-
generative disease, ADCA-DN (OMIM 604121), has been asso-
ciated to mutations in DNMT1 located in the same func-
tional domain (Winkelmann et al., 2012). HSN1E and ADCA-
DN have been initially considered as two distinct clinical
entities, but more recently the evidence of overlapping clini-
cal features, often subclinical, has emerged, strongly suggest-
ing that they can be better considered as phenotypes belong-
ing to the same neurodegenerative spectrum (Moghadam et al.,
2014).
Hereditary sensory neuropathy with dementia and hearing
loss is a severe disorder characterized by both central and periph-
eral nervous system involvement, with peripheral neuropathy
leading to extremity injuries and infections, frequently need-
ing amputations, severe early onset hearing loss, and middle-age
dementia (Hojo et al., 1999; Klein et al., 2011). By a whole-exome
sequencing analysis, two heterozygous mutations in DNMT1
have been identiﬁed as the genetic cause of HSN1E in four unre-
lated families from diﬀerent geographical area (Klein et al., 2011).
A point mutation leading to the p.Tyr511Cys (NP_001124295.1)
aminoacid substitution was found in three families, whereas
three nucleotide changes causing the substitution of two con-
tiguous aminoacids, p.Asp506Glu-Pro507Arg (NP_001124295.1)
were found in the fourth pedigree of this study; both mutations
were located in exon 20 and aﬀected the RFTS domain of DNMT1
(Klein et al., 2011). Through an accurate functional investiga-
tion, Klein et al. (2011) demonstrated that these mutations cause
a premature degradation of the protein, reduced methyltrans-
ferase activity, and impaired binding to heterochromatin in G2
phase, leading to global DNA hypomethylation and site-speciﬁc
hypermethylation.
The abnormal status of DNA methylationinduced by the
p.Tyr511Cys mutation has been thoroughly analyzed by whole-
genome bisulﬁte sequencing in three pairs of HSN1E patients
compared to gender and age-matched siblings, providing an
evaluation of methylation at single base-resolution (Sun et al.,
2014). The results showed prevalent hypomethylation in inter-
genic regions and around the transcription start sites, with the
highest reduction of methylation in chromosomes X and 18
(Sun et al., 2014). Furthermore, using the Ingenuity Pathway
Analysis, the diﬀerentially methylated regions identiﬁed were
linked to “neurological disease,” including progressive neu-
ropathy, PD, AD, ALS, narcolepsy (NC), “psychological disor-
ders,” “skeletal and muscular disorders” and “cancer,” whereas
the most compromised pathway resulted the NAD+/NADH
metabolism, which is also implicated in neurodegeneration
(Sun et al., 2014).
In 2013 two additional cases of HSN1E with psychiatric
manifestations and seizures were identiﬁed, again caused by
mutations in the exon 20 of DNMT1, one of them previ-
ously identiﬁed (p.Tyr511Cys), and one previously unreported
mutation p.Tyr511His (NP_001124295.1), aﬀecting both the
same amino acid residue in the RFTS domain (Klein et al.,
2013). Two other HSN1E families has been described in
2014, presenting mutations in exon 20 of DNMT1: one
point mutation (p.Pro506Arg, NP_001124295.1) hitting the
same amino acid position of another previously reported
case (Klein et al., 2011), and a novel trinucleotide deletion
(p.Lys521del, NP_001124295.1; Moghadam et al., 2014). The
extensive characterization of the HSN1E patients in this latter
study showed that subclinical symptoms usually characterizing
ADCA-DN, such as NC (without cataplexy and with normal
hypocretin-1 level in cerebrospinal ﬂuid) and optic atrophy, may
be present in patients aﬀected by HSN1E, highlighting aphe-
notypic overlap between these two diseases (Moghadam et al.,
2014).
Moreover, the strict association between exon 20 and HSN1E
has been broken by Yuan et al. (2013) a unique case of HSN1E
caused by a novel mutation (p.His569Arg, NP_001124295.1) in
exon 21, that is usually associated with ADCA-DN), but still
aﬀecting the RFTS domain and further remarking the idea of a
continuum.
Autosomal dominant cerebellar ataxia-deafness and
narcolepsy was ﬁrst described by Melberg et al. (1995),
but the genetic cause has been identiﬁed only recently in
Winkelmann et al. (2012). ADCA-DN is initially characterized
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by late-onset NC with or without cataplexy, complicated in later
stages of the disease by sensorineural deafness, cerebellar ataxia,
and dementia appear (Melberg et al., 1995). Mild polyneu-
ropathy, optic atrophy, epilepsy, psychosis, diabetes mellitus,
cardiomyopathy, and progressive cerebral, cerebellar, and
brainstem atrophy may also be present (Melberg et al., 1999;
Winkelmann et al., 2012; Moghadam et al., 2014). DNMT1
mutations in exon 21 have been found to cause ADCA-DN
(Winkelmann et al., 2012), thus qualifying DNMT1 as the third
mutant leading to genetically determined NC (Peyron et al.,
2000; Hor et al., 2011). A previous link between DNMT1
and NC emerged from a genome-wide study associating
NC with the SNP rs4804122, located in a region of high
linkage disequilibrium spanning several genes including
DNMT1, and a weak correlation between this NC-associated
allele and lower DNMT1 mRNA expression was also docu-
mented in peripheral blood mononuclear cells (Kornum et al.,
2011).
Initially, three missense mutations have been identiﬁed in four
diﬀerent families, all aﬀecting the RFTS domain: p.Ala570Val,
p.Val606Phe, p.Gly605Ala (NP_001124295.1). The authors spec-
ulated that these mutations might aﬀect the interaction with
other proteins, i.e., HDAC2, or the DNA- binding, being
close to three phenylalanines critical for the anchoring of
the RFTS domain to the DNA-binding pocket (Takeshita et al.,
2011; Winkelmann et al., 2012). Concerning the role of mutant
DNMT1 in the pathogenesis of NC in ADCA-DN, hypocre-
tin cells, whose loss cause NC, may be particularly suscepti-
ble to altered methylation induced by the DNMT1 mutations
(Winkelmann et al., 2012). Alternatively, the mutations may
impair the regulation and diﬀerentiation of immune cells pos-
sibly promoting an autoimmune reaction (Winkelmann et al.,
2012), thus supporting autoimmunity as the main pathogenic
mechanism of NC (Fontana et al., 2010). This hypothesis is
reinforced by the critical role played by DNMT1for T-cells
development, function and survival (Lee et al., 2001; Wang et al.,
2013). However, the HLA-DQB1∗06:02, which represents the
major genetic risk factor for NC (Tafti et al., 2014), was neg-
ative in all except for two of the ADCA-DN patients with
DNMT1 mutations (Winkelmann et al., 2012; Pedroso et al.,
2013; Moghadam et al., 2014), weakening the autoimmune
hypothesis for this disease. An additional case of ADCA-DN
due to a novel missense mutation in exon 21 of DNMT1,
p.Cys596Arg (NP_001124295.1), has been reported; this patient
displayed the typical, previously described features of the disease
(Pedroso et al., 2013).
Interestingly, HSN1E and ADCA-DN present common fea-
tures resembling mitochondrial encephalomyopathies, such
as sensorineural deafness, optic atrophy, cerebellar involve-
ment, and peripheral neuropathy (Moghadam et al., 2014).
Furthermore, a mitochondrial dysfunction at the biochemical
level was already documented in skeletal muscle of an ADCA-
DN patient in Melberg et al. (1995). In addition, the alteration of
NAD+/NADH-related pathways that emerged from the methy-
lome study on HSN1E (Sun et al., 2014) also reinforces the possi-
bility of mitochondrial dysfunction in the complex pathogenesis
of this disorder.
Furthermore, hypomethylation of nuclear genes with
mitochondrial function has been observed in HSN1E patients
compared to sex and age-matched controls, although a statistical
signiﬁcance was not reached (Sun et al., 2014).
In conclusion, 10 diﬀerent mutations in exons 20 and 21
of the DNMT1 gene have been identiﬁed to date, six caus-
ing HSN1E and four causing ADCA-DN, two distinct dis-
eases now considered as clinical phenotypes of the same dis-
ease spectrum (Moghadam et al., 2014). In fact, all the muta-
tions aﬀect the RFTS domain, which has a regulatory func-
tion for the DNMT1 activity. In particular, mounting evi-
dence demonstrate that this domain has an auto-inhibitory
role (Bashtrykov et al., 2014) and it has been suggested that
its deletion activates DNMT1 for euchromatic DNA-binding,
but at the same time decreases heterochromatin binding prob-
ably through a missing protein interaction, thus producing
passive DNA demethylation (Wu et al., 2014). Moreover, the
RFTS deletion seems to produce a methylation status typical
of cancer, with global hypomethylation and promoter hyper-
methylation, and additional 26 mutations in this domain have
been found in diﬀerent tumors (Forbes et al., 2008; Wu et al.,
2014).
Open questions still have to be addressed. For example, it
is unclear whether mutations in exon 20 and 21 of DNMT1
act through the same pathogenic mechanism, and the methyla-
tion status of ADCA-DN patients has not been investigated yet.
Furthermore, although the altered methylation pattern observed
in HSN1E patients resembles that of tumorigenesis (Sun et al.,
2014) and loss of function of RFTS domain enhances tumori-
genicity (Wu et al., 2014), none of the DNMT1 mutant patients
seem to develop cancer. Lastly, the possible role of mitochon-
drial dysfunction deserves to be unraveled by functional studies,
to shed light on the potential role of mito-epigenetics (from
both nuclear and mitochondrial genomes) in the pathogenic
mechanisms of DNMT1mutations. Tackling all these open ques-
tions will be crucial to understand the pathogenesis of DNMT1
related neurodegeneration, including the narcoleptic features,
but ultimately will also help to resolve the question of mtDNA
methylation.
Final Remarks
The fascinating ﬁeld of epigenetic regulation of gene expression
is fast evolving, as well as the implications in human pathol-
ogy. One point highlighted by reviewing the state of art of this
ﬁeld, and prompted by the recent identiﬁcation of neurodegen-
erative disorders due to pathogenic mutations in the DNMT1
gene, is the role played by the mitochondrial methylome as a
whole, includes obviously the tissue and cell-speciﬁc methylation
pattern of the nuclear mitochondrial proteome (about 1500–
2000 nuclear genes), and the still very controversial existence
of mtDNA methylation. This latter longstanding question needs
to be resolved, and the possible biological function played by
mtDNA methylation in cell physiology may add to the com-
plex inter-genomic dialog between nuclear and mitochondrial
DNAs. The rapidly evolving NGS approaches should allow the
Frontiers in Genetics | www.frontiersin.org 11 March 2015 | Volume 6 | Article 90
Maresca et al. DNMT1 and mtDNA methylation
resolution of the controversies, in conjunction with func-
tional studies, paying attention to the peculiar features of the
mitochondrial genome, which include gene organization, tran-
scription, and replication, and most importantly its multicopy
nature. The nuclear counterpart represented by the growing
list of nuclear genes implicated in mitochondrial biology is
equally crucial for understanding the complexities of can-
cer and neurodegeneration, now fuelled by the existence of
an ideal model to investigate, the DNMT1-related human
diseases.
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